Cargando…

The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook

Dendritic cells (DC) are key phagocytic cells that play crucial roles in both the innate and adaptive immune responses against the human immunodeficiency virus type 1 (HIV-1). By processing and presenting pathogen-derived antigens, dendritic cells initiate a directed response against infected cells....

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Hager, Miller, Vandana, Jennings, Stephen R., Wigdahl, Brian, Krebs, Fred C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267878/
https://www.ncbi.nlm.nih.gov/pubmed/32537473
http://dx.doi.org/10.1155/2020/9470102
_version_ 1783541494844489728
author Mohamed, Hager
Miller, Vandana
Jennings, Stephen R.
Wigdahl, Brian
Krebs, Fred C.
author_facet Mohamed, Hager
Miller, Vandana
Jennings, Stephen R.
Wigdahl, Brian
Krebs, Fred C.
author_sort Mohamed, Hager
collection PubMed
description Dendritic cells (DC) are key phagocytic cells that play crucial roles in both the innate and adaptive immune responses against the human immunodeficiency virus type 1 (HIV-1). By processing and presenting pathogen-derived antigens, dendritic cells initiate a directed response against infected cells. They activate the adaptive immune system upon recognition of pathogen-associated molecular patterns (PAMPs) on infected cells. During the course of HIV-1 infection, a successful adaptive (cytotoxic CD8(+) T-cell) response is necessary for preventing the progression and spread of infection in a variety of cells. Dendritic cells have thus been recognized as a valuable tool in the development of immunotherapeutic approaches and vaccines effective against HIV-1. The advancements in dendritic cell vaccines in cancers have paved the way for applications of this form of immunotherapy to HIV-1 infection. Clinical trials with patients infected with HIV-1 who are well-suppressed by antiretroviral therapy (ART) were recently performed to assess the efficacy of DC vaccines, with the goal of mounting an HIV-1 antigen-specific T-cell response, ideally to clear infection and eliminate the need for long-term ART. This review summarizes and compares methods and efficacies of a number of DC vaccine trials utilizing autologous dendritic cells loaded with HIV-1 antigens. The potential for advancement and novel strategies of improving efficacy of this type of immunotherapy is also discussed.
format Online
Article
Text
id pubmed-7267878
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-72678782020-06-13 The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook Mohamed, Hager Miller, Vandana Jennings, Stephen R. Wigdahl, Brian Krebs, Fred C. J Immunol Res Review Article Dendritic cells (DC) are key phagocytic cells that play crucial roles in both the innate and adaptive immune responses against the human immunodeficiency virus type 1 (HIV-1). By processing and presenting pathogen-derived antigens, dendritic cells initiate a directed response against infected cells. They activate the adaptive immune system upon recognition of pathogen-associated molecular patterns (PAMPs) on infected cells. During the course of HIV-1 infection, a successful adaptive (cytotoxic CD8(+) T-cell) response is necessary for preventing the progression and spread of infection in a variety of cells. Dendritic cells have thus been recognized as a valuable tool in the development of immunotherapeutic approaches and vaccines effective against HIV-1. The advancements in dendritic cell vaccines in cancers have paved the way for applications of this form of immunotherapy to HIV-1 infection. Clinical trials with patients infected with HIV-1 who are well-suppressed by antiretroviral therapy (ART) were recently performed to assess the efficacy of DC vaccines, with the goal of mounting an HIV-1 antigen-specific T-cell response, ideally to clear infection and eliminate the need for long-term ART. This review summarizes and compares methods and efficacies of a number of DC vaccine trials utilizing autologous dendritic cells loaded with HIV-1 antigens. The potential for advancement and novel strategies of improving efficacy of this type of immunotherapy is also discussed. Hindawi 2020-05-25 /pmc/articles/PMC7267878/ /pubmed/32537473 http://dx.doi.org/10.1155/2020/9470102 Text en Copyright © 2020 Hager Mohamed et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Mohamed, Hager
Miller, Vandana
Jennings, Stephen R.
Wigdahl, Brian
Krebs, Fred C.
The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
title The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
title_full The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
title_fullStr The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
title_full_unstemmed The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
title_short The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
title_sort evolution of dendritic cell immunotherapy against hiv-1 infection: improvements and outlook
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267878/
https://www.ncbi.nlm.nih.gov/pubmed/32537473
http://dx.doi.org/10.1155/2020/9470102
work_keys_str_mv AT mohamedhager theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT millervandana theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT jenningsstephenr theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT wigdahlbrian theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT krebsfredc theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT mohamedhager evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT millervandana evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT jenningsstephenr evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT wigdahlbrian evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook
AT krebsfredc evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook